Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A John Barrett

Showing results (61-70 of 162) with videos related to

Pageof 17
Sort By:
Annals of Internal Medicine|August 6, 2002
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromesJeffrey J Molldrem, Eric Leifer, Erkut Bahceci, et al.
Health and Quality of Life Outcomes|April 19, 2011
Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocolMargaret F Bevans, Sandra A Mitchell, A John Barrett, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2011
Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?Mikael Sundin, Pádraig D'arcy, C Christian Johansson, et al.
Blood|November 12, 2005
Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidenceMinoo Battiwalla, Theresa Hahn, Marija Radovic, et al.
British Journal of Haematology|March 5, 2003
Prospective evaluation of cell kinetics, yields and donor experiences during a single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cellsCharles D Bolan, Charles S Carter, Robert A Wesley, et al.
Blood|August 15, 2002
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromeYogen Saunthararajah, Ryotaro Nakamura, Jun-Mo Nam, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2003
New developments in allotransplant immunologyA John Barrett, Katayoun Rezvani, Scott Solomon, et al.
Blood|April 22, 2006
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCTKatayoun Rezvani, Stephan Mielke, Mojgan Ahmadzadeh, et al.
Blood|April 14, 2005
Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndromeElaine M Sloand, Lori Mainwaring, Monika Fuhrer, et al.
Blood|January 26, 2010
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantationAndreas T Björklund, Marie Schaffer, Cyril Fauriat, et al.
Pageof 17

Showing results (61-70 of 162) with videos related to

Sort By:
Pageof 17
Annals of Internal Medicine|August 6, 2002
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromesJeffrey J Molldrem, Eric Leifer, Erkut Bahceci, et al.
Health and Quality of Life Outcomes|April 19, 2011
Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocolMargaret F Bevans, Sandra A Mitchell, A John Barrett, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2011
Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?Mikael Sundin, Pádraig D'arcy, C Christian Johansson, et al.
Blood|November 12, 2005
Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidenceMinoo Battiwalla, Theresa Hahn, Marija Radovic, et al.
British Journal of Haematology|March 5, 2003
Prospective evaluation of cell kinetics, yields and donor experiences during a single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cellsCharles D Bolan, Charles S Carter, Robert A Wesley, et al.
Blood|August 15, 2002
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromeYogen Saunthararajah, Ryotaro Nakamura, Jun-Mo Nam, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2003
New developments in allotransplant immunologyA John Barrett, Katayoun Rezvani, Scott Solomon, et al.
Blood|April 22, 2006
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCTKatayoun Rezvani, Stephan Mielke, Mojgan Ahmadzadeh, et al.
Blood|April 14, 2005
Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndromeElaine M Sloand, Lori Mainwaring, Monika Fuhrer, et al.
Blood|January 26, 2010
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantationAndreas T Björklund, Marie Schaffer, Cyril Fauriat, et al.
Pageof 17